Stockscreener 앱 받기
240.66
0.30%
0.71
시간 외 거래:
240.66
Resmed Inc 주식(RMD)의 최신 뉴스
ResMed Wins Invalidation of Sleep Apnea Tech Patent After Remand - Bloomberg Law News
Is It Smart To Buy ResMed Inc. (NYSE:RMD) Before It Goes Ex-Dividend? - Yahoo Finance
ResMed Corporation: GLP-1 Demand Generation Strategy to Expand Customer Base & Strengthen Their Position! - Smartkarma
Intuitive wins new FDA nod for single port robot; Resmed buys diagnostic facility - MedTech Dive
This ResMed Insider Reduced Their Stake By 72% - Yahoo Finance
Resmed acquires independent diagnostic testing facility VirtuOx - Yahoo Finance
Resmed Acquires Virtual Care Company VirtuOx - Medical Product Outsourcing
ResMed (RMD) Expands with VirtuOx Acquisition - GuruFocus
Resmed Acquires VirtuOx - Nasdaq
ResMed Buys VirtuOx for Undisclosed sum - marketscreener.com
Resmed (RMD) Expands Reach with Acquisition of VirtuOx | RMD Sto - GuruFocus
Resmed acquires virtual diagnostics company VirtuOx - MassDevice
Resmed (RMD) Expands Reach with Acquisition of VirtuOx | RMD Stock News - GuruFocus
Why ResMed (RMD) is a Top Growth Stock for the Long-Term - Yahoo Finance
ResMed announces it has acquired VirtuOx - TipRanks
Resmed Inc (RMD): Jim Cramer Says “Remarkable Stock” — Did GLP-1 Drugs Just Hand It a Lifeline? - Insider Monkey
This ASX medical device company has a Trump tariff exemption - MSN
Resmed Hires Chief Investor Relations Officer - HME Business
Press Release Distribution & PR Platform - ACCESS Newswire
ResMed Inc. Files Quarterly Report, Reinforces Market Position - MSN
ASX healthcare leader continues to prove the doubters wrong - Morningstar
What does Macquarie think ResMed shares are worth? - MSN
ResMed brushes off tariff threat - Intelligent Investor
ResMed Q3 Earnings and Revenues Beat, Stock Up in After-Market - MSN
ResMed Q1 2025: Strong Sales Growth and Strategic InitiativesNews and Statistics - IndexBox
ResMed Inc. (NYSE:RMD) Q3 2025 Earnings Call Transcript - Insider Monkey
ResMed Inc’s Earnings Call Highlights Growth and Innovation - TipRanks
ResMed Inc (RMD)'s Winning Formula: Financial Metrics and Compet - GuruFocus
ResMed (RMD) is a Top-Ranked Momentum Stock: Should You Buy? - Yahoo Finance
Decoding ResMed Inc (RMD): A Strategic SWOT Insight - GuruFocus
ResMed Inc. stock rises Thursday, outperforms market - MSN
ResMed Boasts Double-Digit EPS Growth, Tariff Exemption: Analysts Boost Price ForecastResMed (NYSE:RMD) - Benzinga
ResMed (NYSE:RMD) Reports Strong Q3 Earnings Growth and Declares US$0.53 Dividend - Yahoo Finance
ResMed (RMD) Q3 Earnings and Revenues Surpass Estimates - MSN
ResMed Inc (RMD) Shares Up 11.28% on Apr 24 - GuruFocus
ResMed price target raised to $255 from $247 at RBC Capital - TipRanks
Jefferies Adjusts Price Target on ResMed to $245 From $270, Maintains Hold Rating - marketscreener.com
Morgan Stanley Adjusts Price Target on ResMed to $286 From $280, Maintains Overweight Rating - marketscreener.com
ResMed stock holds as Oppenheimer maintains Perform rating By Investing.com - Investing.com Canada
Texas Instruments Posts Better-Than-Expected Results, Joins Community Health Systems, Hasbro, ServiceNow, ResMed And Other Big Stocks Moving Higher On ThursdayArdagh Metal Packaging (NYSE:AMBP), Allegion (NYSE:ALLE) - Benzinga
Stifel maintains ResMed stock hold rating and $240 target - Investing.com
Stifel maintains ResMed stock hold rating and $240 target By Investing.com - Investing.com UK
ResMed stock price target raised to $255 at RBC Capital - Investing.com
Piper Sandler cuts ResMed stock price target to $248 - Investing.com
Piper Sandler cuts ResMed stock price target to $248 By Investing.com - Investing.com UK
ResMed (RMD) Target Price Lowered by Piper Sandler Following Ear - GuruFocus
ResMed (RMD) Price Target Reduced by Mizuho | RMD Stock News - GuruFocus
Mizuho cuts ResMed stock price target to $250 from $265 By Investing.com - Investing.com India
Mizuho cuts ResMed stock price target to $250 from $265 - Investing.com
ResMed (RMD) Target Price Lowered by Piper Sandler Following Earnings | RMD Stock News - GuruFocus
RBC Capital Lifts ResMed (RMD) Price Target Amid Solid Q3 Performance | RMD Stock News - GuruFocus
ResMed's Moat Is Underpinned by Switching Costs and Intangible Brand Assets - Morningstar
RBC Raises Price Target on ResMed to $255 From $247, Keeps Sector Perform Rating - marketscreener.com
ResMed stock holds as Oppenheimer maintains Perform rating - Investing.com
0.94%
자본화:
|
볼륨(24시간):